Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1619-7089
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate ; day:10 ; month:5 ; year:2016 ; pages:1-10
European journal of nuclear medicine and molecular imaging ; (10.5.2016), 1-10

Urheber
Bergsma, Hendrik
Beteiligte Personen und Organisationen
Konijnenberg, Mark W.
Zwan, Wouter A. van der
Kam, Boen L. R.
Teunissen, Jaap J. M.
Kooij, Peter P.
Mauff, Katya A. L.
Krenning, Eric P.
Kwekkeboom, Dik J.
SpringerLink (Online service)

DOI
10.1007/s00259-016-3382-9
URN
urn:nbn:de:1111-201605114091
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 11:04 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Bergsma, Hendrik
  • Konijnenberg, Mark W.
  • Zwan, Wouter A. van der
  • Kam, Boen L. R.
  • Teunissen, Jaap J. M.
  • Kooij, Peter P.
  • Mauff, Katya A. L.
  • Krenning, Eric P.
  • Kwekkeboom, Dik J.
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China

Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

Prediction of [177Lu]Lu-DOTA-TATE therapy response using the absorbed dose estimated from [177Lu]Lu-DOTA-TATE SPECT/CT in patients with metastatic neuroendocrine tumour

Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy

Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy

177Lu-DOTA-Octreotat bei Radiorezeptortherapie neuroendokriner Tumore: intratherapeutische Dosimetrie und Eliminationskinetik

Hochschulschrift

177Lu-DOTA-Octreotat bei Radiorezeptortherapie neuroendokriner Tumore: intratherapeutische Dosimetrie und Eliminationskinetik

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases

Fernmetastasierte neuroendokrine Tumoren des Pankreas: Ansprechen auf Radiopeptidtherapie mit 177Lu-DOTA-Octreotat

Fernmetastasierte neuroendokrine Tumoren des Pankreas: Ansprechen auf Radiopeptidtherapie mit 177Lu-DOTA-Octreotat

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics

Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics

Verbundene Objekte